Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?

References

• Eli Lilly and Company. Zyprexa (olanzapine). In: Physicians’ Desk Reference, 2009, 63rd Edition. Physicians ’ Desk Reference Inc., Montvale, NJ, USA, 1883–1891 (2008).
   Google Scholar
• Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J. Clin. Psychopharmacol.24(2), 192–208 (2004).
   PubMed Web of Science ®Google Scholar
• Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry60(6), 553–564 (2003).
   PubMed Web of Science ®Google Scholar
• Citrome L, Kantrowitz J. Using antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. Expert Rev. Neurother.8(7), 1079–1091 (2008).
   PubMedGoogle Scholar
• Citrome L, Jaffe A, Levine J. Dosing of second-generation antipsychotic medication in a state hospital system. J. Clin. Psychopharmacol.25(4), 388–391 (2005).
   PubMed Web of Science ®Google Scholar
• Citrome L, Jaffe A, Levine J. Datapoints: the ups and downs of dosing second-generation antipsychotics. Psychiatr. Serv.58(1), 11 (2007).
   PubMedGoogle Scholar
• Grohmann R, Engel RR, Geissler KH, Ruther E. Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study. Pharmacopsychiatry37(Suppl. 1), S27–S38 (2004).
   PubMed Web of Science ®Google Scholar
• Edlinger M, Hausmann A, Kemmler G et al. Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period. Schizophr. Res.77(1), 25–34 (2005).
   PubMed Web of Science ®Google Scholar
• Citrome L, Reist C, Palmer L et al. Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. Schizophr. Res.108(1–3), 238–244 (2009).
   PubMedGoogle Scholar
• Mauri MC, Regispani F, Beraldo S et al. Patterns of clinical use of antipsychotics in hospitalized psychiatric patients. Prog. Neuropsychopharmacol. Biol. Psychiatry29(6), 957–963 (2005).
   PubMedGoogle Scholar
• Botts S, Littrell R, de Leon J. Variables associated with high olanzapine dosing in a state hospital. J. Clin. Psychiatry65(8), 1138–1143 (2004).
   PubMed Web of Science ®Google Scholar
• Heimann SW. High-dose olanzapine in an adolescent. J. Am. Acad. Child Adolesc. Psychiatry38(5), 496–498 (1999).
   PubMed Web of Science ®Google Scholar
• Launer MA. High dose olanzapine in treatment resistant schizophrenia. Schizophr. Res.29(1–2), 149–150 (1998).
   Web of Science ®Google Scholar
• Mountjoy CQ, Baldacchino AM, Stubbs JH. British experience with high-dose olanzapine for treatment-refractory schizophrenia. Am. J. Psychiatry156(1), 158–159 (1999).
   PubMed Web of Science ®Google Scholar
• Baldacchino AM, Stubbs JH, Nevison-Andrews D. The use of olanzapine in non compliant or treatment resistant clozapine populations in hospital. Pharm. J.260(6980), 207–209 (1998).
   Google Scholar
• Lerner V. High-dose olanzapine for treatment-refractory schizophrenia. Clin. Neuropharmacol.26(2), 58–61 (2003).
   PubMed Web of Science ®Google Scholar
• Lambert M, Huber CG, Naber D et al. Treatment of severe agitation with olanzapine in 166 patients with schizophrenia, schizoaffective, or bipolar I disorder. Pharmacopsychiatry41(5), 182–189 (2008).
   PubMedGoogle Scholar
• Sheitman BB, Lindgren JC, Early J, Sved M. High-dose olanzapine for treatment-refractory schizophrenia. Am. J. Psychiatry154(11), 1626 (1997).
   PubMed Web of Science ®Google Scholar
• Alao AO, Armenta WA, Yolles JC. High-dose olanzapine therapy in schizophrenia. Ann. Pharmacother.33(11), 1228 (1999).
   PubMed Web of Science ®Google Scholar
• Reich J. Use of high-dose olanzapine in refractory psychosis. Am. J. Psychiatry156(4), 661 (1999).
   PubMed Web of Science ®Google Scholar
• Fanous A, Lindenmayer JP. Schizophrenia and schizoaffective disorder treated with high doses of olanzapine. J. Clin. Psychopharmacol.19(3), 275–276 (1999).
   PubMed Web of Science ®Google Scholar
• Kosky N. A possible association between high normal and high dose olanzapine and prolongation of the PR interval. J. Psychopharmacol.16(2), 181–182 (2002).
   PubMedGoogle Scholar
• Bronson BD, Lindenmayer JP. Adverse effects of high-dose olanzapine in treatment-refractory schizophrenia. J. Clin. Psychopharmacol.20(3), 382–384 (2000).
   PubMedGoogle Scholar
• Chawla B, Luxton-Andrew H. Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial. Hum. Psychopharmacol.23(3), 211–216 (2008).
   PubMedGoogle Scholar
• De la Fuente JM. Case report: excellent response to long-term higher dose single olanzapine in a case of recurrent brief depression. Pharmacopsychiatry41(4), 156–158 (2008).
   PubMedGoogle Scholar
• Dossenbach MRK, Beuzen JN, Avnon M et al. The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. Clin. Ther.22(9), 1021–1034 (2000).
   PubMed Web of Science ®Google Scholar
• Dursun SM, Gardner DM, Bird DC, Flinn J. Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. Can. J. Psychiatry44(7), 701–704 (1999).
   PubMed Web of Science ®Google Scholar
• Karagianis JL, Baksh A. High-dose olanzapine and prolactin levels. J. Clin. Psychiatry64(10), 1192–1194 (2003).
   PubMedGoogle Scholar
• Karagianis JL, LeDrew KK, Walker DJ. Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up. Curr. Med. Res. Opin.19(6), 473–480 (2003).
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Czobor P, Volavka J et al. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. J. Clin. Psychiatry63(10), 931–935 (2002).
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Volavka J, Lieberman J et al. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. J. Clin. Psychopharmacol.21(4), 448–453 (2001).
   PubMed Web of Science ®Google Scholar
• Martin J, Gomez JC, Garcia-Bernardo E, Cuesta M, Alvarez E, Gurpegui M. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. J. Clin. Psychiatry58(11), 479–483 (1997).
   PubMed Web of Science ®Google Scholar
• McElroy SL, Frye M, Denicoff K et al. Olanzapine in treatment-resistant bipolar disorder. J. Affect. Disord.49(2), 119–122 (1998).
   PubMedGoogle Scholar
• Van Heeringen C, Vandendriessche F, Gillain B, Van Vleymen B. The effect of using orally disintegrating olanzapine tablets on agitation, cooperation, and nurses workload in psychiatric patients. Acta Psychiatrica Belgica106(1), 1–6 (2006).
   Google Scholar
• Thomas P, Srivastava V, Singh A et al. Correlates of response to olanzapine in a North Indian schizophrenia sample. Psychiatry Res.161(3), 275–283 (2008).
   PubMed Web of Science ®Google Scholar
• Baker RW, Kinon BJ, Maguire GA, Liu H, Hill AL. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J. Clin. Psychopharmacol.23(4), 342–348 (2003).
   PubMed Web of Science ®Google Scholar
• Bitter I, Dossenbach MR, Brook S et al. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry28(1), 173–180 (2004).
   PubMed Web of Science ®Google Scholar
• Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter WT Jr. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J. Clin. Psychopharmacol.23(6), 668–671 (2003).
   PubMed Web of Science ®Google Scholar
• Conley RR, Tamminga CA, Bartko JJ et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am. J. Psychiatry155(7), 914–920 (1998).
   PubMed Web of Science ®Google Scholar
• Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry63(6), 622–629 (2006).
   PubMed Web of Science ®Google Scholar
• Kumra S, Kranzler H, Gerbino-Rosen G et al. Clozapine and “high-dose” olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol. Psychiatry63(5), 524–529 (2008).
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med.353(12), 1209–1223 (2005).
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Lieberman JA, Stroup TS et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry163(4), 600–610 (2006).
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Bobo WV, Roy A et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J. Clin. Psychiatry69(2), 274–285 (2008).
   PubMed Web of Science ®Google Scholar
• Mitchell M, Riesenberg R, Bari MA et al. A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects. Clin. Ther.28(6), 881–892 (2006).
   PubMed Web of Science ®Google Scholar
• Stroup T, Lieberman JA, McEvoy JP et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am. J. Psychiatry163(4), 611–622 (2006).
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Birkett MA, Kiesler GM, Wood AJ. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol. Psychiatry49(1), 52–63 (2001).
   PubMed Web of Science ®Google Scholar
• Volavka J, Czobor P, Sheitman B et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am. J. Psychiatry159(2), 255–262 (2002).
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Volavka J, Stauffer V et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J. Clin. Psychopharmacol.28(4), 392–400 (2008).
   PubMed Web of Science ®Google Scholar
• Kluge M, Schuld A, Himmerich H et al. Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J. Clin. Psychopharmacol.27(6), 662–666 (2007).
   PubMed Web of Science ®Google Scholar
• Tohen M, Bowden CL, Smulevich AB et al. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br. J. Psychiatry192(2), 135–143 (2008).
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Czobor P, Volavka J et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am. J. Psychiatry160(2), 290–296 (2003).
   PubMed Web of Science ®Google Scholar
• Volavka J, Czobor P, Cooper TB et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J. Clin. Psychiatry65(1), 57–61 (2004).
   PubMed Web of Science ®Google Scholar
• Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry45(9), 789–796 (1988).
   PubMed Web of Science ®Google Scholar
• Kumra S, Kranzler H, Gerbino-Rosen G et al. Clozapine versus “high-dose” olanzapine in refractory early-onset schizophrenia: an open-label extension study. J. Child Adolesc. Psychopharmacol.18(4), 307–316 (2008).
   PubMed Web of Science ®Google Scholar
• Kay SR, Wolkenfeld F, Murrill LM. Profiles of aggression among psychiatric patients. I. Nature and prevalence. J. Nerv. Ment. Dis.176(9), 539–546 (1988).
   PubMed Web of Science ®Google Scholar
• Krakowski MI, Czobor P, Nolan KA. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. J. Clin. Psychopharmacol.28(5), 485–493 (2008).
   PubMed Web of Science ®Google Scholar
• Stroup TS, Lieberman JA, McEvoy JP et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am. J. Psychiatry164(3), 415–427 (2007).
   PubMed Web of Science ®Google Scholar
• Citrome L, Stroup TS. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Int. J. Clin. Pract.60(8), 933–940 (2006).
   PubMed Web of Science ®Google Scholar
• Citrome L, Macher JP, Salazar DE, Mallikaarjun S, Boulton DW. Pharmacokinetics of aripiprazole and concomitant carbamazepine. J. Clin. Psychopharmacol.27(3), 279–283 (2007).
   PubMed Web of Science ®Google Scholar
• Perry PJ, Lund BC, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J. Clin. Psychopharmacol.21(1), 14–20 (2001).
   PubMed Web of Science ®Google Scholar
• Weiss U, Marksteiner J, Kemmler G, Saria A, Aichhorn W. Effects of age and sex on olanzapine plasma concentrations. J. Clin. Psychopharmacol.25(6), 570–574 (2005).
   PubMed Web of Science ®Google Scholar
• Bigos KL, Pollock BG, Coley KC et al. Sex, race, and smoking impact olanzapine exposure. J. Clin. Pharmacol.48(2), 157–165 (2008).
   PubMed Web of Science ®Google Scholar
• Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther. Drug Monit.25(1), 46–53 (2003).
   PubMed Web of Science ®Google Scholar
• Mauri MC, Steinhilber CPC, Marino R et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur. Psychiatry20(1), 55–60 (2005).
   PubMed Web of Science ®Google Scholar
• Citrome L, Stauffer VL, Chen L et al. Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/day in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. J. Clin. Psychopharmacol.29(3), 278–283 (2009).
   PubMed Web of Science ®Google Scholar
• Morgan M, Hackett LP, Isbister KK. Olanzapine overdose: a series of analytically confirmed cases. Int. Clin. Psychopharmacol.22(3), 183–186 (2007).
   PubMed Web of Science ®Google Scholar
• Citrome L. Olanzapine: interpreting the label change. Int. J. Clin. Pract.61(12), 1960–1962 (2007).
   PubMed Web of Science ®Google Scholar
• Kahn RS, Fleischhacker WW, Boter H et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet371(9618), 1085–1097 (2008).
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet373(9657), 31–41 (2009).
   PubMed Web of Science ®Google Scholar
• Leucht S, Komossa K, Rummel-Kluge C et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatry166(2), 152–163 (2009).
   PubMed Web of Science ®Google Scholar
• Citrome L. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Int. J. Clin. Pract.63(1), 140–150 (2009).
   PubMed Web of Science ®Google Scholar
• Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med.13(9), 1102–1107 (2007).
   PubMed Web of Science ®Google Scholar
• Kantrowitz JT, Citrome L. Olanzapine: review of safety 2008. Expert Opin. Drug Saf.7(6), 761–769 (2008).
   PubMed Web of Science ®Google Scholar
• Kelly DL, Richardson CM, Yu Y, Conley RR. Plasma concentrations of high-dose olanzapine in a double-blind crossover study. Hum. Psychopharmacol.21(6), 393–398 (2006).
   PubMed Web of Science ®Google Scholar
• Krakowski M, Czobor P, Citrome L. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophr. Res.110(1–3), 95–102 (2009).
   PubMed Web of Science ®Google Scholar